Selected Stock Price Target News of the Day — May 12, 2026

Today’s stock price target news covers three distinct analyst stories for May 12, 2026. Five analysts simultaneously initiated coverage on defense drone maker AEVEX Aerospace following the expiration of the IPO quiet period. Three analysts downgraded ZoomInfo Technologies following a sharp full-year guidance cut reported after the market close on May 11. Piper Sandler downgraded LENZ Therapeutics after slow commercial launch results for its VIZZ eye-drop product. AnaChart tracks analyst accuracy across all three names using hit rates from 18 years of closed price target data.

AEVEX Aerospace (AVEX): Five Simultaneous Initiations at IPO Quiet Period Expiry

AEVEX Aerospace priced its initial public offering on April 17, 2026, at $20 per share on the New York Stock Exchange. The San Diego-based company designs and operates unmanned aircraft systems and loitering munitions. Its services also include manned aircraft modification and intelligence analysis for U.S. military and allied nation customers. Today’s five initiations mark the end of the standard underwriter quiet period after the IPO.

Noah Poponak of Goldman Sachs opened coverage with a Buy rating and a $34 price target. Poponak holds a 77.08% hit rate across 253 closed AnaChart forecasts. Goldman Sachs served as a joint lead bookrunner on the AEVEX offering. His $34 target implies a 70% return from the $20 IPO price.

Ronald Epstein of B of A Securities also initiated with a Buy rating and a $34 price target. Epstein carries an 84.8% hit rate across 361 AnaChart forecasts. That accuracy mark is among the strongest in aerospace and defense sector coverage. B of A Securities co-led the AEVEX bookrunning syndicate alongside Goldman Sachs.

Peter Arment of Baird initiated coverage with an Outperform rating and a $38 price target. Arment holds an 85.76% hit rate across 266 AnaChart forecasts. His $38 target is the second-highest among today’s five initiations. Arment covers commercial aviation and defense aerospace at Baird with a long record in the sector.

Brian Gesuale of Raymond James initiated with an Outperform rating and a $35 price target. Gesuale holds a 75.32% hit rate across 231 AnaChart forecasts. Raymond James has a consistent franchise in defense technology equity research. Today’s AEVEX initiation extends that coverage into the unmanned systems market.

Austin Bohlig of Needham initiated with a Buy rating and the highest price target of the group at $45. His $45 target reflects a 125% premium to AEVEX’s $20 IPO price. Bohlig covers defense technology and government services companies for Needham. That $45 target stands $7 above the next-highest initiation estimate from Arment at Baird.

All five initiations carry positive ratings, three Buy equivalents and two Outperform ratings. The uniform bullish stance reflects confidence in AEVEX’s position in the defense unmanned systems market. U.S. military procurement of unmanned aerial systems has expanded across multiple service branches in recent years. AEVEX’s contract base spans domestic military programs and partner nation operators. The five-firm initiation cluster is among the larger post-IPO coverage launches in the defense technology sector this year.

ZoomInfo Technologies (GTM) Stock Price Target News: Three Analyst Downgrades on Guidance Cut

ZoomInfo Technologies reported Q1 2026 earnings on May 11, 2026. Revenue of $310.2 million represented a 1.5% year-over-year increase and a narrow beat versus the $307.9 million consensus estimate. EPS of $0.10 came in below the $0.12 consensus forecast. The guidance revision was the larger concern for analysts covering the stock.

ZoomInfo lowered its full-year 2026 revenue outlook to a range of $1.185 billion to $1.205 billion. That compares to prior guidance of $1.247 billion to $1.267 billion, a midpoint reduction of approximately $62 million. For Q2 2026, ZoomInfo guided revenue of $300 million to $303 million. That range fell below the $312.9 million analyst consensus for the quarter. Three separate analysts issued downgrades on May 12.

Parker Lane of Stifel downgraded ZoomInfo from Buy to Hold and cut the price target from $12 to $4. That is a 66.7% reduction in the price target in a single revision. Lane cited the full-year guidance cut as the primary driver of the rating change. Stifel’s new $4 target implies limited near-term recovery from current levels.

Allan Verkhovski of BTIG downgraded ZoomInfo from Buy to Neutral. Verkhovski did not announce a revised price target alongside today’s downgrade. The move from Buy to Neutral marks a full withdrawal of BTIG’s prior positive stance. BTIG’s directional view now aligns with Stifel’s revised outlook on the stock.

Billy Fitzsimmons of Piper Sandler downgraded ZoomInfo from Neutral to Underweight and cut the price target from $7 to $4. That is a two-step rating reduction to Piper Sandler’s most bearish recommendation. Fitzsimmons’s $4 target matches Stifel’s revised estimate. The convergence of both firms at $4 is a notable alignment among independent analysts.

ZoomInfo operates a go-to-market intelligence platform that helps sales and marketing teams find and target buyers. The company provides contact data, buyer-intent signals, and account targeting tools to enterprise customers. Enterprise software spending has remained compressed as companies reduced go-to-market technology budgets over the past two years. The guidance cut suggests these headwinds are extending into the second half of 2026.

LENZ Therapeutics (LENZ): Piper Sandler Downgrade Follows Slow VIZZ Launch

LENZ Therapeutics reported Q1 2026 results on May 11, 2026. Net revenue was $1.9 million for the quarter, with product sales accounting for $1.7 million. The net loss for the period was $41.5 million. Prescription volume for VIZZ, the company’s once-daily eye drop for age-related near vision loss, grew 19% compared to Q4 2025. Despite that sequential gain, physician adoption and patient uptake have run below management’s internal targets.

Biren Amin of Piper Sandler downgraded LENZ from Overweight to Neutral and cut the price target from $39 to $12. That is a 69.2% reduction in the price target in one move. Amin cited slower-than-expected VIZZ market penetration as the primary reason for the rating change. He holds a 58.9% hit rate across 251 closed AnaChart forecasts.

Matthew Caufield of HC Wainwright maintained his Buy rating on LENZ but lowered his price target from $48 to $38. That is a 20.8% reduction from his prior target. Caufield acknowledged the slower adoption pace but retained a positive long-term view on VIZZ’s commercial potential. He holds a 27.99% hit rate across 162 closed AnaChart forecasts.

The divergence between Amin and Caufield reflects a genuine disagreement on the pace of VIZZ adoption. Amin’s downgrade reflects near-term commercial execution risk after Q1 adoption fell below management targets. Caufield’s maintained Buy reflects a view that physician and patient uptake will accelerate in later quarters. VIZZ treats presbyopia, a condition that affects near vision in most adults over age 40. The product competes in a market that includes Allergan’s Vuity, which launched in 2021.

The full price target history for AVEX, GTM, and LENZ, along with the track record of every analyst and firm named here, lives in the analyst price target dataset. It covers 661,383 price targets and 759,654 ratings from 7,191 analysts (3,754 active, 3,437 retired), across 9,686 tickers and 424 brokers (333 active), spanning 2008 to 2026. Every hit rate cited in today’s post is calculated from closed forecasts in AnaChart’s historical dataset. Visit each analyst’s profile page for a full breakdown of their sector coverage and accuracy record.